Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Cleveland Clinic

Sites in Cleveland, OH

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 7:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1314
Shown on this page
12
Current sort
Recently updated
Campus scope
Cleveland Clinic, Cleveland, OH
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Cleveland Clinic, Cleveland, OH. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 1009–1020 of 1,314 matching trials with a site at Cleveland Clinic, Cleveland, OH.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 2Phase 3 Interventional

A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP

NCT04850118
Site status not listed — check the official record
View directory record Official record
Conditions
X-Linked Retinitis Pigmentosa
Interventions
rAAV2tYF-GRK1-hRPGRco, Control
Biological · Drug
Lead sponsor
Beacon Therapeutics
Industry
Eligibility
12 Years to 50 Years · Male only
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
19
States / cities
Scottsdale, Arizona • Los Angeles, California • Jacksonville, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Nov 4, 2026, 7:04 AM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Making Informed Choices on Incorporating Chemoprevention Into Care (MiCHOICE)

NCT04496739
Site status not listed — check the official record
View directory record Official record
Conditions
Atypical Hyperplasia of the Breast, Lobular Breast Carcinoma In Situ, Pleomorphic Lobular Breast Carcinoma In Situ
Interventions
Cancer Educational Materials, Decision Aid, Interview, Questionnaire Administration
Behavioral · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
412 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2028
U.S. locations
96
States / cities
Antioch, California • Costa Mesa, California • Duarte, California + 67 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Nov 4, 2026, 7:04 AM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Bridging the Gap: Educating Patients on Social Determinants of Health to Improve Epilepsy Surgery Access and Outcomes

NCT07509190
Status at this site: Recruiting
View directory record Official record
Conditions
Epilepsy
Interventions
PEERS Program, Surveys, Focus group
Behavioral · Other
Lead sponsor
Anny Reyes
Other
Eligibility
18 Years and older
Enrollment
310 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Nov 4, 2026, 7:04 AM EST
Active, not recruiting Phase 3 Interventional

Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

NCT04498117
Site status not listed — check the official record
View directory record Official record
Conditions
Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Neoplasms
Interventions
Oregovomab, Paclitaxel, Carboplatin, Placebo
Biological · Drug
Lead sponsor
CanariaBio Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
615 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
81
States / cities
Phoenix, Arizona • Tucson, Arizona • Concord, California + 70 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Nov 4, 2026, 7:04 AM EST
Active, not recruiting Phase 2 Interventional Results available

Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer

NCT01898494
Site status not listed — check the official record
View directory record Official record
Conditions
Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Oropharynx
Interventions
Transoral surgery, intensity-modulated radiation therapy, cisplatin, carboplatin
Procedure · Radiation · Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
519 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
58
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 44 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Nov 4, 2026, 7:04 AM EST
Active, not recruiting No phase listed Observational

DECAMP 1 PLUS: Prediction of Lung Cancer Using Noninvasive Biomarkers

NCT04165564
Site status not listed — check the official record
View directory record Official record
Conditions
Pulmonary Disease
Interventions
Institutional standard of care, Biosamples of airway and blood
Other
Lead sponsor
Boston University
Other
Eligibility
46 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Nov 4, 2026, 7:04 AM EST
Recruiting Not applicable Interventional

Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women

NCT04124120
Status at this site: Not yet recruiting
View directory record Official record
Conditions
Heart Diseases, Coronary Artery Disease, Coronary Artery Bypass Grafting
Interventions
Single arterial graft, Multiple arterial grafting
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older · Female only
Enrollment
2,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
42
States / cities
Los Angeles, California • Pomona, California • San Francisco, California + 36 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Nov 4, 2026, 7:04 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

NCT02138734
Site status not listed — check the official record
View directory record Official record
Conditions
Non-muscle Invasive Bladder Cancer
Interventions
BCG (50mg/instillation) + N-803 (400 μg/instillation), BCG (50mg/instillation)
Biological
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2039
U.S. locations
72
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Nov 4, 2026, 7:04 AM EST
Active, not recruiting Not applicable Interventional

Citadel Embolization Device Study

NCT04057352
Site status not listed — check the official record
View directory record Official record
Conditions
Unruptured Wide-neck Aneurysms
Interventions
Citadel Embolization Device
Device
Lead sponsor
Stryker Neurovascular
Industry
Eligibility
18 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
25
States / cities
Los Angeles, California • San Francisco, California • Walnut Creek, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Nov 4, 2026, 7:04 AM EST
Recruiting Phase 2 Interventional

Sacituzumab Govitecan in Recurrent Glioblastoma

NCT04559230
Status at this site: Recruiting
View directory record Official record
Conditions
Recurrent Glioblastoma
Interventions
Sacituzumab Govitecan
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
3
States / cities
Cleveland, Ohio • Austin, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Nov 4, 2026, 7:04 AM EST
Active, not recruiting Phase 2 Interventional

Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)

NCT04947319
Site status not listed — check the official record
View directory record Official record
Conditions
Refractory Primary Central Nervous System Lymphoma, Primary CNS Lymphoma
Interventions
Tirabrutinib
Drug
Lead sponsor
Ono Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
39
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 32 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Nov 4, 2026, 7:04 AM EST
Active, not recruiting Phase 2 Interventional

A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations

NCT06653842
Site status not listed — check the official record
View directory record Official record
Conditions
Cutaneous Venous Malformations
Interventions
QTORIN 3.9% rapamycin anhydrous gel
Drug
Lead sponsor
Palvella Therapeutics, Inc.
Industry
Eligibility
6 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
10
States / cities
Irvine, California • Palo Alto, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Nov 4, 2026, 7:04 AM EST

About this Cleveland Clinic institution page

What this page lists
ClinicalTrials.gov records that list Cleveland Clinic in Cleveland, OH as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.